What we’ve learned from the Aduhelm mess
STAT publishes selected Letters to the Editor in response to First Opinion essays for robust, good-faith discussion. Jason Karlawish’s article on Aduhelm’s approval process raises concerns about the roles and incentives of pharmaceutical companies and the FDA. John Haaga supports Karlawish’s points and advocates for public funding of FDA and NIH research for objectivity. Adina…